26th Jun 2020 14:50
Hemogenyx Pharmaceuticals PLC - pre-clinical stage biopharmaceutical firm headquartered in London - Signs biological investigation and material supply agreement with an undisclosed "leading global pharmaceutical company". The agreement will see the undisclosed partner supply Hemogenyx "with certain biological materials and related confidential information" so that it can conduct research and development activities in order to find and validate "novel materials" that could treat lupus and potentially other autoimmune diseases. The deal complements Hemogenyx's ongoing work and stipulates that the pharma company's name not be disclosed, though Hemogenyx noted it is the same company with which Hemogenyx is working on its CDX antibody product candidate. Hemogenyx is to grant the company a research licence for anything jointly developed as part of the agreement, plus an option for an exclusive worldwide licence for commercial exploitation of the materials.
Current stock price: 5.89 pence.
Year-to-date change: up more than 200%; 1.93p on January 2
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Hemogenyx